Endocyte Insider Sells $155,000 in Stock (ECYT)
Endocyte (NASDAQ:ECYT) Insider David Meek sold 10,000 shares of Endocyte stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $15.50, for a total transaction of $155,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
ECYT has been the subject of a number of recent research reports. Analysts at Brean Capital initiated coverage on shares of Endocyte (NASDAQ:ECYT) in a research note to investors on Monday. They set a “buy” rating and a $21.00 price target on the stock. Separately, analysts at Credit Suisse raised their price target on shares of Endocyte (NASDAQ:ECYT) from $16.00 to $24.00 in a research note to investors on Monday, August 5th. They now have an “outperform” rating on the stock. Finally, analysts at Roth Capital raised their price target on shares of Endocyte (NASDAQ:ECYT) from $16.00 to $20.00 in a research note to investors on Friday, August 2nd. They now have a “buy” rating on the stock.
One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $19.88.
Endocyte (NASDAQ:ECYT) traded down 5.88% during mid-day trading on Monday, hitting $15.53. 453,164 shares of the company’s stock traded hands. Endocyte has a 52 week low of $7.50 and a 52 week high of $19.00. The stock’s 50-day moving average is $15.96 and its 200-day moving average is $13.89. The company’s market cap is $559.8 million.
Endocyte, Inc (NASDAQ:ECYT) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.